IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact

2.

Davis

LN

,

Sherbenou

DW

.

Emerging therapeutic strategies to overcome drug resistance in multiple myeloma

.

Cancers

.

2021

;

13

(

7

):

1686

.

3.

Bianchi

G

,

Munshi

NC

.

Pathogenesis beyond the cancer clone(s) in multiple myeloma

.

Blood

.

2015

;

125

(

20

):

3049

-

3058

.

4.

Ria

R

,

Vacca

A

.

Bone marrow stromal cells-induced drug resistance in multiple myeloma

.

Int J Mol Sci

.

2020

;

21

(

2

):

613

.

5.

Pawlyn

C

,

Davies

FE

,

Kaiser

MF

, et al.

Primary IMiD refractory myeloma; results from 3894 patients treated in the Phase III Myeloma XI Study

.

Blood

.

2016

;

128

(

22

):

1144

.

6.

Lecat

CSY

,

Taube

JB

,

Wilson

W

, et al.

Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma

.

Front Oncol

.

2021

;

11

:

703233

.

7.

Holstein

SA

,

McCarthy

PL

.

Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience

.

Drugs

.

2017

;

77

(

5

):

505

-

520

.

8.

Singhal

S

,

Mehta

J

,

Desikan

R

, et al.

Antitumor activity of thalidomide in refractory multiple myeloma

.

N Engl J Med

.

1999

;

341

(

21

):

1565

-

1571

.

9.

Ito

T

,

Ando

H

,

Suzuki

T

, et al.

Identification of a primary target of thalidomide teratogenicity

.

Science (New York, NY)

.

2010

;

327

(

5971

):

1345

-

1350

.

10.

Collins

I

,

Wang

H

,

Caldwell

JJ

,

Chopra

R

.

Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway

.

Biochem J

.

2017

;

474

(

7

):

1127

-

1147

.

11.

Kronke

J

,

Hurst

SN

,

Ebert

BL

.

Lenalidomide induces degradation of IKZF1 and IKZF3

.

OncoImmunology

.

2014

;

3

(

7

):

e941742

.

12.

Lu

G

,

Middleton

RE

,

Sun

H

, et al.

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

.

Science (New York, NY)

.

2014

;

343

(

6168

):

305

-

309

.

13.

Shaffer

AL

,

Emre

NCT

,

Lamy

L

, et al.

IRF4 addiction in multiple myeloma

.

Nature

.

2008

;

454

(

7201

):

226

-

231

.

14.

Sievers

QL

,

Petzold

G

,

Bunker

RD

, et al.

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN

.

Science (New York, NY)

.

2018

;

362

(

6414

):

eaat0572

.

15.

An

J

,

Ponthier

CM

,

Sack

R

, et al.

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase

.

Nat Commun

.

2017

;

8

:

15398

.

16.

Chung

D

,

Dellaire

G

.

The role of the COP9 signalosome and neddylation in DNA damage signaling and repair

.

Biomolecules

.

2015

;

5

(

4

):

2388

-

2416

.

17.

Eichner

R

,

Heider

M

,

Fernandez-Saiz

V

, et al.

Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity

.

Nat Med

.

2016

;

22

(

7

):

735

-

743

.

18.

Heider

M

,

Eichner

R

,

Stroh

J

, et al.

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma

.

Mol Cell

.

2021

;

81

(

6

):

1170

-

1186.e10

.

19.

Kortum

KM

,

Zhu

YX

,

Shi

CX

,

Jedlowski

P

,

Stewart

AK

.

Cereblon binding molecules in multiple myeloma

.

Blood Rev

.

2015

;

29

(

5

):

329

-

334

.

20.

D'Souza

C

,

Prince

HM

,

Neeson

PJ

.

Understanding the role of T-cells in the antimyeloma effect of immunomodulatory drugs

.

Front Immunol

.

2021

;

12

:

632399

.

21.

Thakurta

A

,

Pierceall

WE

,

Amatangelo

MD

,

Flynt

E

,

Agarwal

A

.

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma

.

Oncotarget

.

2021

;

12

(

15

):

1555

-

1563

.

22.

Dimopoulos

MA

,

Palumbo

A

,

Corradini

P

, et al.

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

.

Blood

.

2016

;

128

(

4

):

497

-

503

.

23.

Richardson

PG

,

Schjesvold

F

,

Weisel

K

, et al.

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

.

Eur J Haematol

.

2022

;

108

(

1

):

73

-

83

.

24.

van de Donk

NWCJ

,

Popat

R

,

Larsen

J

, et al.

First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed/refractory multiple myeloma (RRMM) [abstract]

.

Blood

.

2020

;

136

(

suppl 1

):

16

-

17

.

25.

Lonial

S

,

van de Donk

NW

,

Popat

R

, et al.

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

.

J Clin Oncol

.

2019

;

37

(

15

):

8006

.

26.

Richardson

PG

,

Trudel

S

,

Quach

H

, et al.

Mezigdomide (CC-92480), a potent, novel cereblon E3 ligase modulator (CELMoD), combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the Dose-Expansion Phase of the CC-92480-MM-001 tria [abstract]l

.

Blood

.

2022

;

140

(

suppl 1

):

1366

-

1368

.

27.

Lonial

S

,

Popat

R

,

Hulin

C

, et al.

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

.

Lancet Haematol

.

2022

;

9

(

11

):

e822

-

e832

.

28.

Zhu

YX

,

Braggio

E

,

Shi

CX

, et al.

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

.

Blood

.

2011

;

118

(

18

):

4771

-

4779

.

29.

Franssen

LE

,

Nijhof

IS

,

Couto

S

, et al.

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients

.

Haematologica

.

2018

;

103

(

8

):

e368

-

e371

.

30.

Sperling

AS

,

Burgess

M

,

Keshishian

H

, et al.

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs

.

Blood

.

2019

;

134

(

2

):

160

-

170

.

31.

Asatsuma-Okumura

T

,

Ito

T

,

Handa

H

.

Molecular mechanisms of cereblon-based drugs

.

Pharmacol Ther

.

2019

;

202

:

132

-

139

.

32.

Carpio

C

,

Bouabdallah

R

,

Ysebaert

L

, et al.

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

.

Blood

.

2020

;

135

(

13

):

996

-

1007

.

33.

Ioannou

N

,

Jain

K

,

Ramsay

AG

.

Immunomodulatory drugs for the treatment of B cell malignancies

.

Int J Mol Sci

.

2021

;

22

(

16

):

8572

.

34.

Churcher

I

.

Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?

.

J Med Chem

.

2018

;

61

(

2

):

444

-

452

.

35.

Lopez-Girona

A

,

Mendy

D

,

Ito

T

, et al.

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

.

Leukemia

.

2012

;

26

(

11

):

2326

-

2335

.

36.

Ocio

EM

,

Fernandez-Lazaro

D

,

San-Segundo

L

, et al.

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

.

Leukemia

.

2015

;

29

(

3

):

705

-

714

.

37.

Liu

J

,

Song

T

,

Zhou

W

, et al.

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity

.

Leukemia

.

2019

;

33

(

1

):

171

-

180

.

38.

Sievers

QL

,

Gasser

JA

,

Cowley

GS

,

Fischer

ES

,

Ebert

BL

.

Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4(CRBN) activity

.

Blood

.

2018

;

132

(

12

):

1293

-

1303

.

39.

Shirasaki

R

,

Matthews

GM

,

Gandolfi

S

, et al.

Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins

.

Cell Rep

.

2021

;

34

(

1

):

108532

.

40.

Skerget

S

,

Benard

B

,

Christofferson

A

, et al.

A molecular analysis of cereblon-related immunomodulatory drug resistance in CoMMpass multiple myeloma patients [abstract]

.

Blood

.

2017

;

130

(

suppl 1

):

1754

.

41.

Kortum

KM

,

Mai

EK

,

Hanafiah

NH

, et al.

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

.

Blood

.

2016

;

128

(

9

):

1226

-

1233

.

42.

Barrio

S

,

Munawar

U

,

Zhu

YX

, et al.

IKZF1/3 and CRL4(CRBN) E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma

.

Haematologica

.

2020

;

105

(

5

):

e237

-

e241

.

43.

Gooding

S

,

Ansari-Pour

N

,

Towfic

F

, et al.

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

.

Blood

.

2021

;

137

(

2

):

232

-

237

.

44.

Neri

P

,

Maity

R

,

Keats

JJ

, et al.

Cereblon splicing of exon 10 mediates IMiDs resistance in multiple myeloma: clinical validation in the CoMMpass Trial

.

Blood

.

2016

;

128

(

22

):

120

.

45.

Haertle

L

,

Barrio

S

,

Munawar

U

, et al.

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

.

Blood

.

2021

;

138

(

18

):

1721

-

1726

.

46.

Dimopoulos

K

,

Sogaard Helbo

A

,

Fibiger Munch-Petersen

H

, et al.

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner

.

Mol Oncol

.

2018

;

12

(

2

):

180

-

195

.

47.

Drew

AE

,

Motwani

V

,

Eichinger

L

,

Smith

J

,

Raimondi

A

.

Mechanism of action of synergistic activity of EZH2 inhibition and IMiDs in preclinical multiple myeloma models [abstract]

.

Cancer Res

.

2018

;

78

(

13

).

48.

Bird

SA

,

Barber

A

,

Sialana

FJ

, et al.

Multiomics analysis of IMiD/CELMoD resistant multiple myeloma models uncovers novel and targetable vulnerabilities in the SREBP lipid synthesis pathway [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

600

-

601

.

49.

Gooding

S

,

Ansari-Pour

N

,

Kazeroun

MH

, et al.

Loss of COP9 signalosome genes at 2q37 is associated with IMiD agent resistance in multiple myeloma

.

Blood

.

2022;140(16):1816-1821

.

50.

Tilmont

R

,

Maity

R

,

Leblay

N

, et al.

CRBN structural changes, copy number changes and COP9 signalosome subunits gene expression mediate sensitivity to new CELMoD compound CC-92480 in multiple myeloma patients [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

9964

-

9965

.

51.

Zhou

N

,

Gutierrez-Uzquiza

A

,

Zheng

XY

, et al.

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation

.

Leukemia

.

2019

;

33

(

8

):

2006

-

2021

.

52.

Barwick

BG

,

Neri

P

,

Bahlis

NJ

, et al.

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

.

Nat Commun

.

2019

;

10

(

1

):

1911

.

53.

Liu

J

,

Hideshima

T

,

Xing

L

, et al.

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment

.

Sci Adv

.

2021

;

7

(

23

):

eabg2697

.

54.

Zhu

YX

,

Shi

CX

,

Bruins

LA

, et al.

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

.

Blood Cancer J

.

2019

;

9

(

2

):

19

.

55.

Neri

P

,

Tagoug

I

,

Maity

R

, et al.

Transcriptional plasticity compensates for Ikaros and Aiolos proteasomal degradation and mediates resistance to IMiDs in multiple myeloma (MM) [abstract]

.

Blood

.

2017

;

130

(

suppl 1

):

63

.

56.

Ng

YLD

,

Ramberger

E

,

Bohl

SR

, et al.

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma

.

Nat Commun

.

2022

;

13

(

1

):

1009

.

57.

Neri

PE

,

Tagoug

I

,

Ren

L

, et al.

Transcriptome profiling of lenalidomide treated myeloma patients identifies an interferon signature gene response and a novel IRF4/MYC independent mechanism of resistance [abstract]

.

Blood

.

2014

;

124

(

21

):

170

.

58.

Van Oekelen

O

,

Amatangelo

M

,

Guo

M

, et al.

Large-scale mass cytometry reveals significant activation of innate and adaptive immunity in bone marrow tumor microenvironment of iberdomide-treated myeloma patients [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

730

.

59.

Chung

DJ

,

Pronschinske

KB

,

Shyer

JA

, et al.

T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy

.

Cancer Immunol Res

.

2016

;

4

(

1

):

61

-

71

.

60.

Batorov

EV

,

Aristova

TA

,

Sergeevicheva

VV

, et al.

Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients

.

Sci Rep

.

2020

;

10

(

1

):

20846

.

61.

van der Veer

MS

,

de Weers

M

,

van Kessel

B

, et al.

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

.

Haematologica

.

2011

;

96

(

2

):

284

-

290

.

62.

van der Veer

MS

,

de Weers

M

,

van Kessel

B

, et al.

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

.

Blood Cancer J

.

2011

;

1

(

10

):

e41

.

63.

Casneuf

T

,

Adams

HC

,

van de Donk

NWCJ

, et al.

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

.

Leukemia

.

2021

;

35

(

2

):

573

-

584

.

64.

Pierceall

WE

,

Amatangelo

MD

,

Bahlis

NJ

, et al.

Immunomodulation in pomalidomide, dexamethasone, and daratumumab-treated patients with relapsed/refractory multiple myeloma

.

Clin Cancer Res

.

2020

;

26

(

22

):

5895

-

5902

.

65.

Tamura

H

,

Ishibashi

M

,

Sunakawa-Kii

M

,

Inokuchi

K

.

PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma

.

Cancers (Basel)

.

2020

;

12

(

4

):

924

.

66.

Mateos

MV

,

Orlowski

RZ

,

Ocio

EM

, et al.

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

.

Br J Haematol

.

2019

;

186

(

5

):

e117

-

e121

.

67.

Mateos

MV

,

Blacklock

H

,

Schjesvold

F

, et al;

KEYNOTE-183 Investigators

.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

.

Lancet Haematol

.

2019

;

6

(

9

):

e459

-

e469

.

68.

Usmani

SZ

,

Schjesvold

F

,

Oriol

A

, et al;

KEYNOTE-185 Investigators

.

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

.

Lancet Haematol

.

2019

;

6

(

9

):

e448

-

e458

.

69.

Gandhi

AK

,

Mendy

D

,

Waldman

M

, et al.

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

.

Br J Haematol

.

2014

;

164

(

2

):

233

-

244

.

70.

Costacurta

M

,

Vervoort

SJ

,

Hogg

SJ

,

Martin

BP

,

Johnstone

RW

,

Shortt

J

.

Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma

.

Haematologica

.

2021

;

106

(

7

):

2013

-

2017

.

71.

Lopez-Girona

A

,

Havens

CG

,

Lu

G

, et al.

CC-92480 is a novel cereblon E3 ligase modulator with enhanced tumoricidal and immunomodulatory activity against sensitive and resistant multiple myeloma cells [abstract]

.

Blood

.

2019

;

134

(

suppl 1

):

1812

.

72.

Hansen

JD

,

Correa

M

,

Nagy

MA

, et al.

Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma

.

J Med Chem

.

2020

;

63

(

13

):

6648

-

6676

.

73.

Walker

ZJ

,

VanWyngarden

MJ

,

Stevens

BM

, et al.

Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression

.

Blood Adv

.

2020

;

4

(

8

):

1628

-

1639

.

74.

Broyl

A

,

Kuiper

R

,

van Duin

M

, et al;

Dutch-Belgian HOVON group

German GMMG Group

.

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance

.

Blood

.

2013

;

121

(

4

):

624

-

627

.

75.

Misiewicz-Krzeminska

I

,

Corchete

LA

,

Rojas

EA

, et al.

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility

.

Haematologica

.

2018

;

103

(

5

):

880

-

889

.

76.

Misiewicz-Krzeminska

I

,

de Ramón

C

,

Corchete

LA

, et al.

Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma

.

Blood Adv

.

2020

;

4

(

23

):

6023

-

6033

.

77.

Agnarelli

A

,

Chevassut

T

,

Mancini

EJ

.

IRF4 in multiple myeloma-Biology, disease and therapeutic target

.

Leuk Res

.

2018

;

72

:

52

-

58

.

78.

Walker

BA

,

Boyle

EM

,

Wardell

CP

, et al.

Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma

.

J Clin Oncol

.

2015

;

33

(

33

):

3911

-

3920

.

79.

Ferguson

ID

,

Patiño-Escobar

B

,

Tuomivaara

ST

, et al.

The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance

.

Nat Commun

.

2022

;

13

(

1

):

4121

.

80.

Bjorklund

CC

,

Kang

J

,

Amatangelo

M

, et al.

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

.

Leukemia

.

2020

;

34

(

4

):

1197

-

1201

.

81.

Lonial

S

,

Shambavi

R

,

Matous

JV

, et al.

Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM [abstract]

.

Cancer Res

.

2022

;

82

(

12

).

82.

Yamamoto

J

,

Suwa

T

,

Murase

Y

, et al.

ARID2 is a pomalidomide-dependent CRL4(CRBN) substrate in multiple myeloma cells

.

Nat Chem Biol

.

2020

;

16

(

11

):

1208

-

1217

.

83.

Wang

S

,

Li

Z

,

Gao

S

.

Key regulators of sensitivity to immunomodulatory drugs in cancer treatment

.

Biomark Res

.

2021

;

9

(

1

):

43

.

84.

Yamamoto

J

,

Ito

T

,

Yamaguchi

Y

,

Handa

H

.

Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders

.

Chem Soc Rev

.

2022

;

51

(

15

):

6234

-

6250

.

85.

Shimizu

N

,

Asatsuma-Okumura

T

,

Yamamoto

J

,

Yamaguchi

Y

,

Handa

H

,

Ito

T

.

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates

.

Commun Biol

.

2021

;

4

(

1

):

1277

.

86.

Chopra

R

,

Sadok

A

,

Collins

I

.

A critical evaluation of the approaches to targeted protein degradation for drug discovery

.

Drug Discov Today Technol

.

2019

;

31

:

5

-

13

.

87.

Gao

S

,

Wang

S

,

Song

Y

.

Novel immunomodulatory drugs and neo-substrates

.

Biomark Res

.

2020

;

8

(

1

):

2

.

88.

Wu

W

,

Nelson

GM

,

Koch

R

, et al.

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

.

Blood

.

2022

;

139

(

13

):

2024

-

2037

.

89.

Jones

JR

,

Barber

A

,

Le Bihan

YV

, et al.

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs

.

Leukemia

.

2021

;

35

(

10

):

3017

-

3020

.

90.

Matyskiela

ME

,

Zhang

W

,

Man

HW

, et al.

A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos

.

J Med Chem

.

2018

;

61

(

2

):

535

-

542

.